CPG 7909 Adjuvant plus Hepatitis B Virus Vaccination in HIV‐Infected Adults Achieves Long‐Term Seroprotection for Up to 5 Years

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.

BACKGROUND Human immunodeficiency virus (HIV)-infected persons are hyporesponsive to hepatitis B virus (HBV) vaccination. CPG 7909 is an oligodeoxynucleotide containing immunostimulatory CpG motifs that activate human B and plasmacytoid dendritic cells via Toll-like receptor 9. We previously reported that addition of CPG 7909 to a commercial HBV vaccine enhanced the kinetics, magnitude, and lon...

Impact of hepatitis B immunization among the Nicobarese tribe - antibody titres & seroprotection five years after vaccination

BACKGROUND & OBJECTIVES A total of 237 Nicobarese subjects who had received hepatitis B vaccination as part of mass vaccination project during 2000-2001 were screened for anti-HBsAg titres by quantitative ELISA five years after vaccination. METHODS Anti-HBsAg antibody was estimated using quantitative ELISA. Proportion of the subjects with protective levels of antibody and geometric mean antib...

Hepatitis B Virus Vaccination in Hemodialysis Patients: A Necessity for Individualizing of Immunization?

Hepatitis B seroprotection in children aged 10 – 15 years after completion of basic hepatitis B immunizations

Background The prevalence of hepatitis B viral (HBV) infection in Indonesia is high. The most effective way to control HBV infection is by hepatitis B (HB) immunization. Many studies reported that hepatitis B surface antibody (anti-HBs) seroprotection declines in children > 10 years of age. In addition many factors can influence anti-HBs titer. Objective To measure anti-HBs titer and evaluate p...

Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan

INTRODUCTION There are controversies over the long-term persistence of post vaccination immunity to hepatitis B and the need for booster doses of the vaccine. The aim of this study was to verify antibody levels of antibody against hepatitis B virus surface antigen (anti-HBs) in children aged 1 to 15 years who received vaccination against hepatitis B in the central province of Iran, Semnan. MA...